Prialt Review Shows Swing In FDA’s Statistical Preference

FDA reanalyzed Elan's Prialt (ziconotide) data using its now-preferred conservative technique for imputation of missing data in chronic pain trials to assuage concerns that the protocol-specified analysis could magnify treatment effect